Submit Covaxin Phase 3 efficacy data before seeking nod for kids trials: SEC

Submit Covaxin Phase 3 efficacy data before seeking nod for kids trials: SEC The Subject Expert Committee (SEC), which advises the Indian drug regulator Drugs Controller General of India (DCGI), has asked Bharat Biotech to submit efficacy and safety data from its ongoing Phase III Covaxin trials before seeking approval for conducting trials on children. https://ift.tt/eA8V8J

Comments

Popular posts from this blog

SC transfers PIL seeking implementation of law on mental health care to NHRC

Hospital-insurer conflict: Will latest circular by NMC help in reducing the pain of health insurance policyholders?

Over 9.19 crore hospital admissions facilitated under Ayushman Bharat since 2018